OWEN KATEY EINTERZ
Known title: DirectorCIK: 0001852578
Associated companies
Transaction History
| ADPT | ▼ Sell | Gift | 12,539 | — | 8/31/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 9,615 | $250K | 8/26/2026 | View on chart |
| ADPT | ▲ Buy | Grant | 15,625 | $0 | 3/4/2026 | View on chart |
| ADPT | ▲ Buy | Grant | 15,394 | $0 | 3/4/2025 | View on chart |
| ADPT | ▲ Buy | Grant | 31,328 | $0 | 3/4/2024 | View on chart |
| ADPT | ▲ Buy | Grant | 14,775 | $0 | 3/6/2023 | View on chart |
| ADPT | ▲ Buy | Grant | 6,689 | $0 | 1/26/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism
Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism. Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.